Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Biogen Inc

BIIB
Current price
156.32 USD -0.98 USD (-0.62%)
Last closed 157.78 USD
ISIN US09062X1037
Sector Healthcare
Industry Drug Manufacturers - General
Exchange NASDAQ
Capitalization 23 931 432 960 USD
Yield for 12 month -36.48 %
1Y
3Y
5Y
10Y
15Y
BIIB
21.11.2021 - 28.11.2021

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts. Address: 225 Binney Street, Cambridge, MA, United States, 02142

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

254.26 USD

P/E ratio

14.8624

Dividend Yield

Current Year

+9 835 600 000 USD

Last Year

+10 173 400 000 USD

Current Quarter

+2 465 800 000 USD

Last Quarter

+2 353 000 000 USD

Current Year

+7 302 200 000 USD

Last Year

+7 895 100 000 USD

Current Quarter

+1 827 100 000 USD

Last Quarter

+1 648 200 000 USD

Key Figures BIIB

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA 2 884 999 936 USD
Operating Margin TTM 20.74 %
PE Ratio 14.8624
Return On Assets TTM 4.99 %
PEG Ratio 6.2424
Return On Equity TTM 10.47 %
Wall Street Target Price 254.26 USD
Revenue TTM 9 607 499 776 USD
Book Value 112.28 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -2.5 %
Dividend Yield
Gross Profit TTM 7 895 100 000 USD
Earnings per share 11.05 USD
Diluted Eps TTM 11.05 USD
Most Recent Quarter III 2024
Quarterly Earnings Growth YOY -1.7 %
Profit Margin 16.81 %

Dividend Analytics BIIB

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History BIIB

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 3:1
Payout Ratio
Last Split Date 18.01.2001
Dividend Date

Stock Valuation BIIB

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 14.8624
Forward PE 9.4429
Enterprise Value Revenue 2.9517
Price Sales TTM 2.4909
Enterprise Value EBITDA 10.1382
Price Book MRQ 1.4308

Financials BIIB

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators BIIB

For 52 weeks

153.62 USD 268.3 USD
50 Day MA 178.64 USD
Shares Short Prior Month 3 120 565
200 Day MA 206.33 USD
Short Ratio 1.74
Shares Short 2 695 410
Short Percent 2.09 %